Androgen composition for treating an opthalmic condition
The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.
1. An ophthalmic emulsion comprising testosterone in an amount of about 0.03 w/w % and castor oil, wherein the emulsion is suitable for topical administration to an eye.
2. The emulsion of claim 1 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
3. The emulsion of claim 1 , further comprising an agent selected from the group consisting of an anti-inflammatory, antimicrobial, analgesic, anesthetic, lubricating agent, and a combination thereof.
4. The emulsion of claim 1 , further comprising a solubility enhancing agent.
5. A method for treating an ocular condition resulting from an androgen deficiency comprising administering the ophthalmic emulsion of claim 1 to a patient in need thereof, wherein at least one symptom of the ocular condition is alleviated.
6. The method of claim 5 , wherein the ocular condition is blepharitis.
7. The method of claim 5 , wherein the ophthalmic emulsion comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
8. The method of claim 5 , further comprising an agent selected from the group consisting of an anti-inflammatory, antibiotic, analgesic, anesthetic, lubricating agent, soothing agent, and a combination thereof.
9. The method of claim 5 , wherein symptoms associated with the ocular condition are reduced.
10. The method of claim 5 , wherein symptoms associated with the ocular condition are eliminated.
11. The method of claim 5 , wherein the administration is repeated until one or more symptoms of the ocular condition are reduced.
12. The method of claim 5 , wherein the administration is repeated until one or more symptoms of the ocular condition are eliminated.
13. The method of claim 5 , wherein the ophthalmic emulsion is administered to the eye, upper lid, lower lid, or a combination thereof.
14. An ophthalmic emulsion comprising testosterone in an amount of about 0.1 w/w % and castor oil, wherein the emulsion is suitable for topical administration to an eye.
15. The emulsion of claim 14 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
16. The emulsion of claim 14 , further comprising an agent selected from the group consisting of an anti-inflammatory, antimicrobial, analgesic, anesthetic, lubricating agent, and a combination thereof.
17. The emulsion of claim 14 , further comprising a solubility enhancing agent.
18. An ophthalmic emulsion comprising testosterone in an amount of about 0.3 w/w % and castor oil, wherein the emulsion is suitable for topical administration to an eye.
19. The emulsion of claim 18 , wherein the emulsion further comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
20. The emulsion of claim 18 , further comprising an agent selected from the group consisting of an anti-inflammatory, antimicrobial, analgesic, anesthetic, lubricating agent, and a combination thereof.
21. The emulsion of claim 18 , further comprising a solubility enhancing agent.
22. A method for treating an ocular condition resulting from an androgen deficiency comprising administering the ophthalmic emulsion of claim 14 to a patient in need thereof, wherein at least one symptom of the ocular condition is alleviated.
23. The method of claim 22 , wherein the ocular condition is blepharitis.
24. The method of claim 22 , wherein the ophthalmic emulsion comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
25. The method of claim 22 , further comprising an agent selected from the group consisting of an anti-inflammatory, antibiotic, analgesic, anesthetic, lubricating agent, soothing agent, and a combination thereof.
26. The method of claim 22 , wherein symptoms associated with the ocular condition are reduced.
27. The method of claim 22 , wherein symptoms associated with the ocular condition are eliminated.
28. The method of claim 22 , wherein the administration is repeated until one or more symptoms of the ocular condition are reduced.
29. The method of claim 22 , wherein the administration is repeated until one or more symptoms of the ocular condition are eliminated.
30. The method of claim 22 , wherein the ophthalmic emulsion is administered to the eye, upper lid, lower lid, or a combination thereof.
31. A method for treating an ocular condition resulting from an androgen deficiency comprising administering the ophthalmic emulsion of claim 18 to a patient in need thereof, wherein at least one symptom of the ocular condition is alleviated.
32. The method of claim 31 , wherein the ocular condition is blepharitis.
33. The method of claim 31 , wherein the ophthalmic emulsion comprises an additional constituent selected from the group consisting of a thickener, neutralizing agent, emulsifier, buffering agent, tonicity agent, demulcent, preservative, plasticizer, occlusive agent, film former, and a combination thereof.
34. The method of claim 31 , further comprising an agent selected from the group consisting of an anti-inflammatory, antibiotic, analgesic, anesthetic, lubricating agent, soothing agent, and a combination thereof.
35. The method of claim 31 , wherein symptoms associated with the ocular condition are reduced.
36. The method of claim 31 , wherein symptoms associated with the ocular condition are eliminated.
37. The method of claim 31 , wherein the administration is repeated until one or more symptoms of the ocular condition are reduced.
38. The method of claim 31 , wherein the administration is repeated until one or more symptoms of the ocular condition are eliminated.
39. The method of claim 31 , wherein the ophthalmic emulsion is administered to the eye, upper lid, lower lid, or a combination thereof.